Results 21 to 30 of about 303,574 (253)
Current Problems in Cancer: Case Reports, 2021 Patients with metastatic renal cell carcinoma are often affected by metastases to the brain that result in significant complications as well as limitations in clinical trial participation.
Cierra Hong +5 more
doaj +1 more source
Frontiers in Oncology, 2021 Posttransplant lymphoproliferative disorder (PTLD) is a rare complication after allogeneic hematopoietic stem cell transplantation (allo-HSCT) with poor prognosis.
Ting-Ting Yang +17 more
doaj +1 more source
Dynamics of mutant BCR-ABL-positive clones after cessation of tyrosine kinase inhibitor therapy
Haematologica, 2011 Background Point mutations of the BCR-ABL tyrosine kinase domain are considered the predominant cause of imatinib resistance in chronic myeloid leukemia.
Benjamin Hanfstein +9 more
doaj +1 more source
Novel Multitarget Therapies for Lung Cancer and Respiratory Disease
Molecules, 2020 In recent years, multitarget drugs for neurological diseases such as Alzheimer’s disease have been developed and well researched. Many studies have revealed that multitarget drugs are also useful for lung cancer and respiratory diseases.
Masako Yumura +2 more
doaj +1 more source
Nilotinib-Associated Destructive Thyroiditis
Case Reports in Endocrinology, 2015 Protein tyrosine kinase inhibitors are currently an important drug class in the treatment of leukemia. They represent targeted cancer therapy and have become the treatment of choice in chronic myeloid leukemia.
Suhalia Bakerywala +4 more
doaj +1 more source
Haematologica, 2013 There have been few reports of a response to dasatinib or nilotinib after failure of two prior sequential tyrosine kinase inhibitors. We report the outcome of 82 chronic phase patients who received nilotinib or dasatinib as third-line alternative ...
Antonella Russo Rossi +19 more
doaj +1 more source
Tyrosine kinase inhibitor Tofacitinib. Safety issues
Медицинский совет, 2015 Tofacitinib (TOFA) was the first synthetic small molecule drug which was comparable with genetically engineered biological agents (GIBA) in terms of its therapeutic effect in rheumatoid arthritis (RA).
G. V. Lukina, Y. A. Sigidin
doaj +1 more source
Haematologica, 2017 Nearly one-third of patients with acute myeloid leukemia have FMS-like tyrosine kinase 3 mutations and thus have poor survival prospects. Receptor tyrosine kinase anexelekto is critical for FMS-like tyrosine kinase 3 signaling and participates in FMS ...
Peter P. Ruvolo +11 more
doaj +1 more source
Lichen planopilaris-like eruption during treatment with tyrosine kinase inhibitor nilotinib [PDF]
Anais Brasileiros de Dermatologia, 2016 Tyrosine kinase inhibitors are effective as a target therapy for malignant neoplasms. Imatinib was the first tyrosine kinase inhibitor used. After its introduction, several other drugs have appeared with a similar mechanism of action, but less prone to ...
Juliana Ribeiro Leitão +4 more
doaj +1 more source
Haematologica, 2011 Background It has not been clearly established whether second-generation tyrosine kinase inhibitors actually improve the survival of patients with chronic myeloid leukemia in chronic phase who are given nilotinib or dasatinib therapy after treatment ...
Amr R. Ibrahim +9 more
doaj +1 more source